NEOGENOMICS INC (NEO) Stock Price, Quote, News and Overview
NASDAQ:NEO - Nasdaq - US64049M2098 - Common Stock - Currency: USD
NEO Quote, Performance and Key Statistics
6.58
-3.39 (-34%)
The current stock price of NEO is 6.58 USD. In the past month the price decreased by -30.66%. In the past year, price decreased by -56.99%.
NEO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CI | THE CIGNA GROUP | 12.33 | 91.42B | ||
| CVS | CVS HEALTH CORP | 12 | 82.09B | ||
| LH | LABCORP HOLDINGS INC | 16.5 | 20.12B | ||
| DGX | QUEST DIAGNOSTICS INC | 19.42 | 19.92B | ||
| FMS | FRESENIUS MEDICAL CARE-ADR | 13.5 | 14.66B | ||
| DVA | DAVITA INC | 14.9 | 11.32B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 114.07 | 10.98B | ||
| CHE | CHEMED CORP | 24.39 | 8.40B | ||
| HIMS | HIMS & HERS HEALTH INC | 64.89 | 7.78B | ||
| GH | GUARDANT HEALTH INC | N/A | 6.11B | ||
| CRVL | CORVEL CORP | 26.08 | 5.60B | ||
| OPCH | OPTION CARE HEALTH INC | 25.16 | 5.04B |
Related stock screener links
About NEO
Company Profile
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company is headquartered in Fort Myers, Florida and currently employs 2,200 full-time employees. The company went IPO on 2012-12-10. The firm offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. The company operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
Company Info
NEOGENOMICS INC
9490 Neogenomics Way
Fort Myers FLORIDA 33913 US
CEO: Douglas M. VanOort
Employees: 2100
Company Website: https://neogenomics.com/
Investor Relations: https://ir.neogenomics.com/
Phone: 12397680600
NEOGENOMICS INC / NEO FAQ
What is the stock price of NEOGENOMICS INC today?
The current stock price of NEO is 6.58 USD. The price decreased by -34% in the last trading session.
What is the ticker symbol for NEOGENOMICS INC stock?
The exchange symbol of NEOGENOMICS INC is NEO and it is listed on the Nasdaq exchange.
On which exchange is NEO stock listed?
NEO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NEOGENOMICS INC stock?
19 analysts have analysed NEO and the average price target is 18.53 USD. This implies a price increase of 181.61% is expected in the next year compared to the current price of 6.58. Check the NEOGENOMICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NEOGENOMICS INC worth?
NEOGENOMICS INC (NEO) has a market capitalization of 846.58M USD. This makes NEO a Small Cap stock.
How many employees does NEOGENOMICS INC have?
NEOGENOMICS INC (NEO) currently has 2100 employees.
Is NEOGENOMICS INC (NEO) expected to grow?
The Revenue of NEOGENOMICS INC (NEO) is expected to grow by 11.7% in the next year. Check the estimates tab for more information on the NEO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NEOGENOMICS INC (NEO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NEO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NEO, evaluating the profitability, health, valuation and growth aspects
- NEOGENOMICS INC (NEO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NEOGENOMICS INC (NEO) Sales and EPS estimates to see what analysts future expectations are.
- NEOGENOMICS INC (NEO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NEOGENOMICS INC (NEO) Insider and Institutional Ownership to learn about the owners and their transactions.
- NEOGENOMICS INC (NEO) Stock Chart to make your own analysis
- NEOGENOMICS INC (NEO) Latest news and press-releases to stay up to date.
Does NEOGENOMICS INC (NEO) stock pay dividends?
NEO does not pay a dividend.
When does NEOGENOMICS INC (NEO) report earnings?
NEOGENOMICS INC (NEO) will report earnings on 2025-04-29, before the market open.
What is the Price/Earnings (PE) ratio of NEOGENOMICS INC (NEO)?
The PE ratio for NEOGENOMICS INC (NEO) is 65.8. This is based on the reported non-GAAP earnings per share of 0.1 and the current share price of 6.58 USD. Check the full fundamental report for a full analysis of the valuation metrics for NEO.
What is the Short Interest ratio of NEOGENOMICS INC (NEO) stock?
The outstanding short interest for NEOGENOMICS INC (NEO) is 3.91% of its float. Check the ownership tab for more information on the NEO short interest.
NEO Technical Analysis
NEO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NEO. NEO has a bad profitability rating. Also its financial health evaluation is rather negative.
NEO Financial Highlights
Over the last trailing twelve months NEO reported a non-GAAP Earnings per Share(EPS) of 0.1. The EPS increased by 190.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.81% | ||
| ROE | -8.72% | ||
| Debt/Equity | 0.38 |
NEO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to NEO. The Buy consensus is the average rating of analysts ratings from 19 analysts.
For the next year, analysts expect an EPS growth of 82.07% and a revenue growth 11.7% for NEO